Zacks: Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) to Post -$0.23 EPS
Equities research analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report earnings of ($0.23) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Celldex Therapeutics’ earnings, with estimates ranging from ($0.34) to ($0.19). Celldex Therapeutics reported earnings per share of ($0.30) during the same quarter last year, which would suggest a positive year-over-year growth rate of 23.3%. The company is scheduled to report its next earnings results on Tuesday, March 13th.
According to Zacks, analysts expect that Celldex Therapeutics will report full year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.06) to ($0.86). For the next year, analysts anticipate that the business will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.09) to ($0.59). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Celldex Therapeutics.
A number of equities analysts have weighed in on the stock. BidaskClub raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 22nd. HC Wainwright set a $10.00 price target on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research note on Friday, February 9th. Finally, WBB Securities reaffirmed a “buy” rating and set a $10.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $7.05.
A number of hedge funds have recently made changes to their positions in CLDX. Vanguard Group Inc. grew its holdings in Celldex Therapeutics by 7.8% during the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after acquiring an additional 708,095 shares in the last quarter. Millennium Management LLC grew its holdings in Celldex Therapeutics by 21.8% during the 4th quarter. Millennium Management LLC now owns 2,241,521 shares of the biopharmaceutical company’s stock worth $6,366,000 after acquiring an additional 400,965 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in Celldex Therapeutics during the 2nd quarter worth $943,000. Dimensional Fund Advisors LP grew its holdings in Celldex Therapeutics by 69.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 832,186 shares of the biopharmaceutical company’s stock worth $2,056,000 after acquiring an additional 339,639 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Celldex Therapeutics by 741.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 352,511 shares of the biopharmaceutical company’s stock worth $1,008,000 after acquiring an additional 310,638 shares in the last quarter. 57.55% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/03/05/zacks-brokerages-anticipate-celldex-therapeutics-inc-cldx-to-post-0-23-eps.html.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.